Amended Trial: Lova Sun Describes Important Changes to the EA3231 Study for Patients With BRAF-Mutated Differentiated Thyroid Cancer

Research definition

Trial Results: ECOG-ACRIN Research Round-Up

November 19, 2026
Evaluation Form

35 Member Networks and Programs Receive Commendations in 2026 for Research Performance

November 19, 2026
Research definition

Trial Results: ECOG-ACRIN Research Round-Up

November 19, 2026
Evaluation Form

35 Member Networks and Programs Receive Commendations in 2026 for Research Performance

November 19, 2026

Amended Trial: Lova Sun Describes Important Changes to the EA3231 Study for Patients With BRAF-Mutated Differentiated Thyroid Cancer

EA3231 – A Randomized Phase III Study of BRAF-Targeted Therapy vs Cabozantinib in RAI-Refractory Differentiated Thyroid Cancer with BRAF V600E

By Lova Sun, MD, MSCE

@LovaSunMD

The expanding number of treatment options for radioactive iodine (RAI)-refractory differentiated thyroid cancer (DTC) has created an important question for clinicians: What is the best way to sequence these therapies when a patient’s cancer progresses?

EA3231 is seeking to answer that question for patients whose tumors harbor a BRAF V600E mutation. The phase 3 trial compares the BRAF-targeted combination of dabrafenib and trametinib versus cabozantinib following progression on frontline multikinase inhibitor (MKI) therapy. By directly comparing these approaches, investigators hope to determine whether BRAF-targeted therapy can improve progression-free survival while offering a more tolerable treatment option.

The study builds on the US Food and Drug Administration’s 2022 tumor-agnostic approval of dabrafenib plus trametinib for advanced BRAF V600E-mutated solid tumors. It could help clarify where targeted therapy belongs in the treatment sequence for this patient population.

Amendment #6 activated on October 22, 2026, and includes numerous important changes to the trial, outlined below.

Eligibility Criteria

  • RECIST 1.1 measurable radiographic progression is no longer required; radiographic progression definitions have been updated (refer to criterion 3.1.7)
  • Prior BRAF and/or MEK therapy for limited duration (< 6 months) as redifferentiation therapy, which must have been completed ≥ 6 months prior to randomization, is now allowed (see criterion 3.1.6)
  • Patients with high-grade differentiated DTC are now eligible
  • It has been clarified that patients with Hürthle cell (oncocytic) are eligible
  • Eligibility criteria regarding uncontrolled hypertension, concomitant anticoagulants, and corrected QTcF have been removed

Treatment Plan

  • The accrual goal has been reduced to 132 patients (n=120 analyzable patients)
  • A 40 mg cabozantinib dosing option has been added (per investigator discretion); dose level reductions for a 40 mg starting dose have been added (see Section 5.3.2)
  • Treatment crossover language has been removed throughout the protocol
  • Language describing non-protocol therapy has been added (see Sections 5.6 and 7.1)

Measurement of Effect

  • A disease progression assessment for patients without RECIST-measurable disease has been added (see Section 6)

Quality-of-Life (QOL) Component

  • The QOL portion of this study has been discontinued; QOL collection has been removed from the protocol

This is not a complete list of all changes to the protocol. Please review the updated protocol carefully for complete details (posted at ctsu.cancer.gov). Study resources have been updated to reflect Amendment #6 and are available for download at ctsu.cancer.gov or on the EA3231 Educational Materials page of ecog-acrin.org.

Learn more about EA3231 at ecog-acrin.org.


Dr. Sun (University of Pennsylvania/Abramson Cancer Center) is the study chair for this trial. The study co-chair is Nabil F. Saba, MD (Emory University/Winship Cancer Institute), and the community co-chair is Mei Tang, MD (Greater Baltimore Medical Center).

The NCTN group study champions are Cristina Rodriguez, MD (University of Washington/UW Medicine Fred Hutchinson Cancer Center) for NRG Oncology, Paul Loren Swiecicki, MD (University of Michigan/UM Health Rogel Cancer Center) for SWOG, and Ari Rosenberg, MD (University of Chicago/UChicago Medicine Comprehensive Cancer Center) for Alliance.

Leave a Reply

Your email address will not be published. Required fields are marked *

Please DO NOT include personal medical information, diagnoses, treatment details, medical record numbers, or other sensitive health information in this form.